Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.

25 Jun 2010

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

Cytomegalovirus (CMV) disease is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-SCT), which is widely accepted as a curative therapy for advanced hematological malignancies including leukemia and malignant lymphoma.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

23 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

Michigan State University researchers analyze histiocytic sarcomas

Michigan State University veterinarians are taking part in a two-year, $5.3 million project to analyze five cancers in dogs, research that could offer new insight into canine cancer genes and their potential impact on the human form of the disease.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study's design, timing and regulatory review.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

For healthcare professionals diagnosing primary Sj-gren's Syndrome (pSS, an autoimmune disorder in which immune cells attack and destroy moisture-producing glands), the incidence of blood based deficiencies is the strongest predictor of a poor outcome in patients according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

19 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.

18 Jun 2010

Pan-Canadian Cancer Research Strategy to maximize impact of cancer research funding

A new strategy to help coordinate cancer research investment across Canada will enable the country's cancer research funders to make faster progress on shared priorities and maximize the impact of cancer research funding in Canada - in turn enabling more Canadians to benefit from new discoveries.

17 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.

15 Jun 2010

Lymphoma News and Research

Further Reading

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Michigan State University researchers analyze histiocytic sarcomas

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

Protect Your Lungs, LUNGevity Foundation announce merger

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Pan-Canadian Cancer Research Strategy to maximize impact of cancer research funding

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Researchers examine rates of cancer in British white and British Indian population

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News